Northsea: NASH candidate data coming soon
It will soon be known whether Northsea Therapeutics’s main asset, a treatment candidate for non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has passed a crucial test.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Altimmune meets NASH goal in phase I
For subscribers
Pfizer drops phase II-ready NASH candidate
For subscribers